CA1175741A - Composition and method for the treatment of cancer - Google Patents
Composition and method for the treatment of cancerInfo
- Publication number
- CA1175741A CA1175741A CA000388472A CA388472A CA1175741A CA 1175741 A CA1175741 A CA 1175741A CA 000388472 A CA000388472 A CA 000388472A CA 388472 A CA388472 A CA 388472A CA 1175741 A CA1175741 A CA 1175741A
- Authority
- CA
- Canada
- Prior art keywords
- brain tissue
- mammal
- tissue
- treatment
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 201000011510 cancer Diseases 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 title abstract description 47
- 238000000034 method Methods 0.000 title abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 210000005013 brain tissue Anatomy 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 239000000725 suspension Substances 0.000 claims abstract description 9
- 210000000944 nerve tissue Anatomy 0.000 claims abstract description 7
- 108010074605 gamma-Globulins Proteins 0.000 claims abstract description 6
- 210000001519 tissue Anatomy 0.000 claims description 33
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 241000283690 Bos taurus Species 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 210000005171 mammalian brain Anatomy 0.000 claims 8
- 239000002131 composite material Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 4
- 102000018358 immunoglobulin Human genes 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 108010034634 Repressor Proteins Proteins 0.000 description 16
- 102000009661 Repressor Proteins Human genes 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 11
- 108010050904 Interferons Proteins 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 241000699800 Cricetinae Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 10
- 230000001173 tumoral effect Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 108700005075 Regulator Genes Proteins 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 6
- 230000035699 permeability Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14541980A | 1980-05-01 | 1980-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1175741A true CA1175741A (en) | 1984-10-09 |
Family
ID=22513026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000388472A Expired CA1175741A (en) | 1980-05-01 | 1981-10-22 | Composition and method for the treatment of cancer |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5874615A (OSRAM) |
| CA (1) | CA1175741A (OSRAM) |
| CH (1) | CH655659B (OSRAM) |
| DE (1) | DE3116733A1 (OSRAM) |
| ES (1) | ES501835A0 (OSRAM) |
| FR (1) | FR2481602A1 (OSRAM) |
| GB (1) | GB2075988B (OSRAM) |
| MX (1) | MX6826E (OSRAM) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2717227A (en) * | 1954-12-22 | 1955-09-06 | Helen L Dawson | Composition containing nerve tissue extract and process of producing such extract |
| DE1095464B (de) * | 1956-05-22 | 1960-12-22 | Univ Tulane | Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten |
-
1981
- 1981-04-28 DE DE19813116733 patent/DE3116733A1/de not_active Withdrawn
- 1981-04-29 FR FR8108520A patent/FR2481602A1/fr active Granted
- 1981-04-30 GB GB8113341A patent/GB2075988B/en not_active Expired
- 1981-04-30 MX MX819434U patent/MX6826E/es unknown
- 1981-04-30 ES ES501835A patent/ES501835A0/es active Granted
- 1981-05-01 CH CH286381A patent/CH655659B/de not_active IP Right Cessation
- 1981-10-22 CA CA000388472A patent/CA1175741A/en not_active Expired
- 1981-10-30 JP JP56174406A patent/JPS5874615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES8300477A1 (es) | 1982-11-01 |
| ES501835A0 (es) | 1982-11-01 |
| JPS5874615A (ja) | 1983-05-06 |
| GB2075988B (en) | 1983-09-01 |
| MX6826E (es) | 1986-08-08 |
| GB2075988A (en) | 1981-11-25 |
| FR2481602A1 (fr) | 1981-11-06 |
| DE3116733A1 (de) | 1982-04-01 |
| CH655659B (OSRAM) | 1986-05-15 |
| FR2481602B1 (OSRAM) | 1984-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buinauskas et al. | Role of operative stress on the resistance of the experimental animal to inoculated cancer cells | |
| Kilham et al. | Viral etiology of spontaneous ataxia of cats | |
| Forsythe et al. | Enuresis and the Electric Alarm—A Study of 200 Cases | |
| Mann et al. | Metabolism of glycerol, sorbitol and related compounds by spermatozoa | |
| US4559228A (en) | Composition and method for the treatment of cancer | |
| CH657376A5 (en) | Process for the preparation of gamma-globulin for intravenous injection | |
| CA1175741A (en) | Composition and method for the treatment of cancer | |
| US4728511A (en) | Composition and method for the treatment of cancer | |
| DE3011461A1 (de) | Verwendung von propionibakterien | |
| AU609909B2 (en) | Urease antigen product & process | |
| Meuwissen et al. | Suppression of graft versus host reaction by mitomycin C | |
| DE3539775A1 (de) | Neues lymphokin, gegen dieses lymphokin spezifische antikoerper, verfahren zu ihrer herstellung und ihre verwendung | |
| Miller | Recovery from irradiation following the administration of cultured tissues | |
| Hawgood | Sir Charles James Martin MB FRS: Australian serpents and Indian plague, one-hundred years ago | |
| EP0100366A1 (en) | Agent for treating allergic disease, immunity complex disease, and tumour | |
| JPS5816687A (ja) | リンホトキシンの製造方法 | |
| JPS62116519A (ja) | 人胎盤抽出細胞代謝活性化物質 | |
| DE1617886A1 (de) | Verfahren zur Herstellung von Arzneimitteln mit selektivem Tropismus gegen Krebs und bestimmte Organe | |
| DE3319360A1 (de) | Pepsinartiges human-leukozyten-enzym, verfahren zur herstellung des enzyms und therapeutische zusammensetzung, welches dasselbe als wirkstoff enthaelt, sowie verwendung der zusammensetzung zur bekaempfung allergischer stoerungen, immunkomplex-erkrankungen und von tumoren | |
| JPH03504507A (ja) | 癌細胞の選択的解離および傷、ケロイド、および炎症の後処理のために用いられる活性物質として適用される植物の光合成系由来タンパク質分画と、該タンパク質分画を含む薬剤学的産物 | |
| Seller | Serotonin as a Teratogen | |
| DE3249946C2 (de) | hTNF-haltiges therapeutisches Mittel gegen maligne Tumoren und dessen Verwendung | |
| Dick et al. | A streptococcus producing symptoms of chorea in a dog | |
| Butler Jr et al. | Biologic effects of specific antibodies in reversing the pharmacologic and toxic effects of digoxin | |
| Price et al. | Treatment of acute gonorrhoea by means of a new gonococcal vaccine of low toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |